Syra Rx safety information

This page collects the safety information that matters for the medications available through Syra Rx. It is written to be useful rather than reassuring. If you are considering a GLP-1 medication or a peptide prescription, this is the material you should read before the marketing copy, not after.

What the compounded label means for safety

Syra Rx states that compounded drugs are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness or quality. It also states that compounded medications are produced in FDA-registered facilities. Those two statements are both true and are often confused with each other.

Term	What it actually means
FDA-approved drug	The FDA has reviewed clinical trial data and concluded the drug is safe and effective for a specific use, and has approved its labelling and manufacturing.
FDA-registered facility	The facility has registered with the FDA and is subject to inspection. This says nothing about whether a particular drug made there has been reviewed.
Compounded drug	Prepared by a licensed pharmacy to meet a specific patient need. Legal where requirements are met. Not FDA-approved, and not reviewed for safety, effectiveness or quality.

In practice this means batch-to-batch consistency, potency verification and the formulation itself depend on the compounding pharmacy’s own standards rather than on FDA review of that product. A reputable, state-licensed pharmacy takes this seriously. But the regulatory safety net is a different one from the one covering an approved brand-name product, and you should know which you are relying on.

Common side effects of GLP-1 medications

Most are gastrointestinal, and most are worst in the first weeks and after each dose increase:

• Nausea — the most frequently reported
• Vomiting
• Diarrhoea or constipation
• Abdominal pain, bloating, reflux
• Reduced appetite, which is also the intended effect
• Fatigue and headache, often linked to eating and drinking less

Dehydration is a common and under-appreciated knock-on problem: eating less, drinking less, and losing fluid through vomiting or diarrhoea together place strain on the kidneys.

Serious effects that warrant prompt medical attention

• Severe, persistent abdominal pain, especially radiating to the back, which can indicate pancreatitis
• Gallbladder symptoms — upper right abdominal pain, fever, jaundice
• Signs of a serious allergic reaction — swelling, difficulty breathing, rash
• A lump or swelling in the neck, hoarseness, difficulty swallowing — report promptly given the thyroid C-cell signal
• Symptoms of low blood sugar, particularly if you also take insulin or a sulfonylurea
• Vision changes, particularly with existing diabetic retinopathy
• Signs of dehydration or reduced kidney function

If you experience any of these, contact a healthcare professional. Do not wait for a scheduled check-in.

Questions worth asking before you start

• Which pharmacy is dispensing this, and is it state-licensed?
• Is what I am being prescribed compounded or an FDA-approved brand-name product?
• What exactly is in the formulation — is anything combined with the active ingredient?
• What is the starting dose and the titration schedule?
• How should it be stored, and what do I do if the cold chain is broken in transit?
• Who do I contact if I have a side effect, and how fast is the response?
• What is the plan if I need to stop?

On the third question specifically: the FDA has taken issue with compounded GLP-1 preparations that combine the active ingredient with additives such as B vitamins and are marketed as “personalised”. Research has found that compounding tirzepatide with B12 can produce chemical interaction not present in the approved drug. If a formulation includes extras, ask why.

Peptide safety

NAD+, sermorelin and tesamorelin have thinner long-term safety data in the uses they are commonly marketed for than GLP-1 medications do, and the regulatory treatment of compounded peptides has been shifting. Thinner data means unknowns, not safety. Ask the prescribing clinician directly about what is known and not known.

Reporting a problem

If you experience a serious adverse event with any medication, tell your prescriber, and consider reporting it to the FDA’s MedWatch programme. Adverse event reporting is how safety signals get detected.

Not medical advice. This page is general safety education and is not a complete list of risks, side effects or interactions. Always read the information that comes with your medication and consult a qualified healthcare professional.